Objective We investigated changes in HDL protein profiling in rheumatoid arthritis patients who started with TNF-inhibitors, stratified for EULAR response.
Introduction
There is abundant data that rheumatoid arthritis (RA) is associated with an increased cardiovascular (CV) risk (1) . Multiple studies have shown that TNF-inhibitors reduce the CV risk in patients with established RA (2) . Suppression of inflammation, e.g. as a result of anti-inflammatory treatment with TNF-inhibitors, leads to increased HDL levels, but also to increased TC levels with virtually no change in TC/HDL ratio (3) , an important predictor of CV events (4) . Hence, the atheroprotective effect of TNF-inhibitors appears not to be mediated by quantitative changes in the lipid profile.
Recent data indicate that TNF-inhibitors induce structural changes in lipid but also protein composition such as decreasing levels of the atherogenic SAA within High Density Lipid (HDL) particles (5) . These findings are important as they may explain the beneficial effect of anti-TNF treatment on CV risk. Therefore, we investigated the changes in HDL protein profiling in RA patients who started with TNF-inhibitors, stratified for EULAR response.
Methods

Study population and design
One hundred, at baseline TNF-naïve, patients with RA were randomly selected from two simultaneously running prospective cohorts at the outpatient rheumatology clinic at Reade, Centre for Rehabilitation and Rheumatology, Amsterdam, the Netherlands.
Treatment allocation was at the discretion of the treating rheumatologist. The etanercept RA cohort comprised 203 patients and the adalimumab RA cohort comprised 204 patients.
In order to distinguish between patients with low and high-grade inflammation only patients with sustained EULAR good or non-response at either 1 and 4 months of TNF blocking therapy were included and moderate responders were excluded. Etanercept treated patients were matched for age, gender, disease duration and baseline DAS to adalimumab treated patients. In total, 50 EULAR good responders and 50 EULAR nonresponders were enrolled in this study. Clinical data and blood samples were collected at baseline and after 1 and 4 months of therapy.
The study was approved by the local Medical Ethics Committee and all patients gave written informed consent.
Assessment of lipids and HDL protein profiling
Total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL), high density lipoprotein (HDL), apolipoproteins (Apo) A-I, A-II, B, E and CIII. TC and TG were measured by enzymatic methods using clinical chemistry analyzers. HDL was determined enzymatically with polyethylene glycol (PEG) modified enzymes. Direct LDL measurement was done with a kit from Wako Chemicals (Neuss, Germany). Apolipoproteins were measured by an immunoturbidimetric method, using assays supplied by Randox Laboratories Limited (Crumlin, UK). TC/HDL ratio and Apo B/ApoA-I ratios were calculated.
HDL profiling was assessed with surface enhanced laser desorption/ionization time-offlight mass spectrometry (SELDI-TOF-MS) (6, 7).
HDL associated proteins were measured directly from fresh frozen plasma and non-HDL components were eliminated by using anti-Apo A-I antibodies. SELDI-TOF analysis was performed with PBS IIc protein chip reader using an automated data collection protocol within Protein-Chip software. Data were collected up to 200 kDa. Laser intensity was set in a range from 190 to 220 relative units and the focus mass was set to 28 kDa for anti-Apo A-I capture. Protein spectra were measured with approximately 100 shots at 13 positions per SELDI spot. The sensitivity of detection was set at signal/noise ratio > 5. Statistical analyses were performed using SPSS version 16.0. The differences between groups were tested using independent t-test, chi-square test or Mann-Whitney U test, as appropriate.
Results
Clinical and demographic characteristics of all patients are shown in table 1. There were no significant differences between etanercept and adalimumab treated patients (data not shown).
Absolute changes in lipid levels were assessed using generalized estimating equation (GEE) analysis. HDL and ApoA did not change in EULAR non responders. In the EULAR good responders, however HDL and ApoAII significantly increased after one and four months of therapy (table 2) . At baseline there were no significant differences in HDL profiling between EULAR good responders and non-responders. There is strong evidence that HDL is atheroprotective, although during inflammation the HDL protein composition changes rendering HDL to a pro-inflammatory and atherogenic state (9) . For example, in response to inflammation SAA replaces Apo A-I from the HDL particle resulting in a decreased ability of HDL to protect LDL from oxidation (10).
The CV risk reduction by TNF-inhibitors in RA patients appears not to be mediated by quantitative changes of the lipids as the effect on the atherogenic index is only very modest (3). Our present data suggest that atheroprotective changes in HDL particle are the consequence of inflammation reduction by potent anti-TNF therapy. This was illustrated by the mass charge markers representing HDL associated SAA-1 and -2, since these markers decreased significantly in good EULAR responders but did not change in EULAR non-responders.
Inherent to the design of this study selection bias should be taken into account. Moreover, SELDI-TOF MS approach was used to assess HDL profiling because of its strong applicability in high throughput sample measurement. This method has limitations such as lack of direct protein identification (6) . However protein profiling and not protein identification was the major objective in this study justifying this approach.
Despite the limitations, this study clearly demonstrates that successful reduction of inflammation in RA patients with anti-TNF therapy restores the HDL protein composition to an atheroprotective profile and therefore underscoring the need of tight inflammation control in RA patients in order to decrease the CV risk. However, it remains to be determined in long-term prospective studies whether these changes in the HDL protein composition translate into meaningful reduction of CV risk in patients with RA.
